WO2005116210A3 - Sirna und shrna gegen stat6 zur behandlung allergischer erkrankungen, pathologischer atemwegsveränderungen und von krebs - Google Patents

Sirna und shrna gegen stat6 zur behandlung allergischer erkrankungen, pathologischer atemwegsveränderungen und von krebs Download PDF

Info

Publication number
WO2005116210A3
WO2005116210A3 PCT/DE2005/000775 DE2005000775W WO2005116210A3 WO 2005116210 A3 WO2005116210 A3 WO 2005116210A3 DE 2005000775 W DE2005000775 W DE 2005000775W WO 2005116210 A3 WO2005116210 A3 WO 2005116210A3
Authority
WO
WIPO (PCT)
Prior art keywords
stat6
shrna
cancer
treatment
respiratory system
Prior art date
Application number
PCT/DE2005/000775
Other languages
English (en)
French (fr)
Other versions
WO2005116210A2 (de
Inventor
Wolfgang Henke
Original Assignee
Halmon Beheer B V
Wolfgang Henke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halmon Beheer B V, Wolfgang Henke filed Critical Halmon Beheer B V
Priority to EP05753636A priority Critical patent/EP1751285A2/de
Publication of WO2005116210A2 publication Critical patent/WO2005116210A2/de
Publication of WO2005116210A3 publication Critical patent/WO2005116210A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft eine pharmazeutische Zusammensetzung enthaltend ein die Stat6 mRNA Expression inhibierendes Oligonukleotid in physiologisch wirksamer Dosis.
PCT/DE2005/000775 2004-05-26 2005-04-25 Sirna und shrna gegen stat6 zur behandlung allergischer erkrankungen, pathologischer atemwegsveränderungen und von krebs WO2005116210A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05753636A EP1751285A2 (de) 2004-05-26 2005-04-25 Sirna und shrna gegen stat6 zur behandlung allergischer erkrankungen, pathologischer atemwegsveränderungen und von krebs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200410026309 DE102004026309A1 (de) 2004-05-26 2004-05-26 Pharamzeutische Zusammensetzung zur Behandlung allergischer Erkrankungen, pathologischer Atemswegsveränderungen und von Krebs durch Modulation der Genexpression des Stat6
DE102004026309.4 2004-05-26

Publications (2)

Publication Number Publication Date
WO2005116210A2 WO2005116210A2 (de) 2005-12-08
WO2005116210A3 true WO2005116210A3 (de) 2006-06-22

Family

ID=35229596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/000775 WO2005116210A2 (de) 2004-05-26 2005-04-25 Sirna und shrna gegen stat6 zur behandlung allergischer erkrankungen, pathologischer atemwegsveränderungen und von krebs

Country Status (3)

Country Link
EP (1) EP1751285A2 (de)
DE (1) DE102004026309A1 (de)
WO (1) WO2005116210A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050655A1 (de) * 2006-10-24 2008-04-30 Halmon Beheer B.V. Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
JP2010068723A (ja) * 2008-09-16 2010-04-02 Tokyo Medical & Dental Univ アレルギー疾患の治療のための核酸医薬
EP2408458A1 (de) * 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-schnittstellen-vermittelte unterdrückung der signal transducer and activator of transcription 6 (stat6) genexpression mit short interfering nucleic acid (sina)
CN114099641A (zh) * 2021-11-09 2022-03-01 苏州大学 Stat6基因为靶点在制备用于治疗急性肺损伤的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040478A2 (en) * 1997-03-13 1998-09-17 Novartis Ag Antisense inhibition of human stat-6
WO2003104277A2 (en) * 2002-01-22 2003-12-18 Asahi Kasei Kabushiki Kaisha Stat6 activation gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040478A2 (en) * 1997-03-13 1998-09-17 Novartis Ag Antisense inhibition of human stat-6
WO2003104277A2 (en) * 2002-01-22 2003-12-18 Asahi Kasei Kabushiki Kaisha Stat6 activation gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOHAPATRA SHYAM S: "Gene transfer and transcription factors. 1-6 March 2002, New York City, NY, USA.", IDRUGS : THE INVESTIGATIONAL DRUGS JOURNAL. APR 2002, vol. 5, no. 4, April 2002 (2002-04-01), pages 312 - 315, XP009057021, ISSN: 1369-7056 *
PENG QI ET AL: "Signaling pathways regulating interleukin-13-stimulated chemokine release from airway smooth muscle.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 169, no. 5, 11 December 2003 (2003-12-11), pages 596 - 603, XP002353987, ISSN: 1073-449X *
POPESCU F -D: "New asthma drugs acting on gene expression", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 7, no. 4, December 2003 (2003-12-01), pages 475 - 486, XP002353988, ISSN: 1582-1838 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds

Also Published As

Publication number Publication date
EP1751285A2 (de) 2007-02-14
WO2005116210A2 (de) 2005-12-08
DE102004026309A1 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2014022739A3 (en) Modified rnai agents
EP2007398A4 (de) Hohe freisetzungsraten für wirkstoffformulierungen auf lipidbasis und behandlungsverfahren damit
IL206296A (en) History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
EP1737428A4 (de) Makromolekulare abgabesysteme für die nichtinvasive darstellung, untersuchung und behandlung von arthritis und anderen entzündlichen erkrankungen
WO2006133707A3 (en) Anti-cancer combination treatment and kit-of-part
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2005116210A3 (de) Sirna und shrna gegen stat6 zur behandlung allergischer erkrankungen, pathologischer atemwegsveränderungen und von krebs
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2009138507A3 (en) Anti-cancer combination therapy
WO2008103916A3 (en) Compositions and methods for treating cancer or a neurotrophic disorder
WO2008039409A3 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
WO2007128588A3 (de) Glutadon
IL195096A (en) Use of aqueous solution of tobacco leaf extract to manufacture a drug for the treatment of tobacco dependence and kits containing it
WO2007108004A8 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005753636

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005753636

Country of ref document: EP